C5C8713B-05C1-4C5C-8685-2A546B99BA50
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 27.33245729303548
- age_years
- 65
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.577
- G2M_CHECKPOINT+0.569
- INTERFERON_ALPHA_RESPONSE+0.536
- INTERFERON_GAMMA_RESPONSE+0.495
- MTORC1_SIGNALING+0.481
- MYC_TARGETS_V1+0.473
- DNA_REPAIR+0.467
- UNFOLDED_PROTEIN_RESPONSE+0.446
- GLYCOLYSIS+0.422
- OXIDATIVE_PHOSPHORYLATION+0.416
Top 10 suppressed
- KRAS_SIGNALING_DN-0.339
- PANCREAS_BETA_CELLS-0.334
- SPERMATOGENESIS-0.278
- MYOGENESIS-0.205
- APICAL_SURFACE-0.116
- ESTROGEN_RESPONSE_EARLY+0.022
- XENOBIOTIC_METABOLISM+0.059
- KRAS_SIGNALING_UP+0.062
- HEDGEHOG_SIGNALING+0.073
- HEME_METABOLISM+0.078
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.970 |
| 2 | 46061E4B-5256-42AD-BA9A-FBCEBE92B09A | — | — | 0.969 |
| 3 | DE370889-1057-4355-AFD8-CCFCDC6CD00F | — | — | 0.967 |
| 4 | 228C2042-804C-47FA-B565-1993E1015D40 | — | — | 0.964 |
| 5 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.964 |
| 6 | DC01D165-E257-49D6-8B9B-37CA7DE398F6 | — | — | 0.961 |
| 7 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.960 |
| 8 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.960 |
| 9 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.959 |
| 10 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.959 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.577 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.569 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.536 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.495 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.481 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.473 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.467 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.446 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.422 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.416 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.414 | Inavolisib | — uncovered |
| HYPOXIA | 0.413 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.397 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.389 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.377 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.359 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.359 | Idelalisib | — uncovered |
| APOPTOSIS | 0.345 | Idelalisib | — uncovered |